PDCD1 and metastatic neoplasm: In 2016 Immune Checkpoint Inhibitors (ICIs) entered the clinical practice for HNSCC with the approval of the anti-Programmed cell Death protein 1 (PD-1) antibodies Nivolumab and Pembrolizumab for patients with recurrent or metastatic tumors (5).